Latest Blogs

May 20, 2019
Health Equity Committee chair Dr. William D. Tap highlights the recent work and forward momentum of ASCO's efforts to achieve health care equity for all through improved access to and quality of care.
May 20, 2019
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
May 17, 2019
To help you get the most out of #ASCO19, I'm sharing a vlog on networking (it's not as scary as you think!) and strategies for organizing your schedule and maximizing your face time with the people you want to meet.
May 16, 2019
My patient had struggled emotionally throughout the course of her cancer treatment, until the day I walked into the room and noticed a profound change.
Subscribe to this column

Matthew S. Katz, MD

Matthew S. Katz, MD, is the Medical Director of Radiation Oncology at Lowell General Hospital and a partner in Radiation Oncology Associates, PA. He is former Chair of the Communications Committee for the American Society for Radiation Oncology (ASTRO) and External Advisory Board member for Mayo Clinic Center for Social Media. He serves on ASCO's Social Media Working Group, ASTRO's Education Committee, and Massachusetts Medical Society's Communications Committee. His areas of prime interest are patient education and health empowerment. Follow Dr. Katz on Twitter @subatomicdoc.

Nov 15, 2018
During my career, pathologists have always been the “doctor’s doctor.” Why can't they be the "patient's doctor" as well?
Dec 06, 2017
Only 11% of randomized trials give enough detail to practically use in clinical practice. Here are five ways we can use internet-based communication to make it easier for academic innovators to get credit for their work, and  to implement new findings for our patients.
Jul 12, 2017
Here are 10 reasons why we should look at postoperative radiation for regional melanoma.
Jul 19, 2016
Drug companies play a key role in improving cancer care, but financial toxicity for patients continues to worsen. Eternal vigilance is the price of liberty from excessive drug costs, and we have an ethical obligation to hold pharmaceutical companies accountable.
Apr 08, 2016
We have discussed risk, biology, and the importance of complete reporting. So how do we decide to actually use RNI?
Apr 04, 2016
How we report clinical trials makes interpreting their results harder. Why shouldn’t we all have more information to make better decisions for our patients?

Pages